In a nutshell
This study aimed to investigate the safety and effectiveness of stereotactic body radiation therapy (SBRT) as a treatment for prostate cancer. This study found that SBRT is a safe and effective option for low and medium risk prostate cancer.
Stereotactic body radiotherapy (SBRT) is a treatment option for prostate cancer. SBRT is different from typical radiation therapy treatment. It can be carried out in fewer treatments and is very precise. It delivers a higher dose of radiation per treatment from different directions. A treatment schedule could be 40Gy in 5 treatments. Gy is the unit of measurement for radiation. The long-term safety and effectiveness of SBRT are still unknown.
Methods & findings
This study included 309 patients with prostate cancer treated with SBRT. 172 low-risk and 137 medium-risk patients were treated in 21 centers. They received 40Gy in 5 treatments. Patients were followed up for an average of 61 months.
95.6% of patients were alive 5 years after treatment. 97.1% of patients were tumor free at 5 years. Low-risk patients had a tumor-free 5-year survival of 97.3%. This rate was 97.1% in the medium-risk group.
Side-effects were mainly minor, including diarrhea and skin soreness. 4 patients experienced more serious side-effects, such as blood in the urine.
The bottom line
This study found that SBRT is an effective and safe treatment option for low and medium risk prostate cancer.
The fine print
Late side-effects could occur after SBRT. Longer-term follow-up studies are needed.
Published By :
International journal of radiation oncology, biology, physics
Sep 26, 2018
If you sign up for Medivizor, you'll receive PERSONALIZED updates that are JUST FOR YOU. Want to give it a try?